EIKCS 2021: Biomarkers for kidney cancer
Dr Thomas Powles from St Barts Hospital, London spoke about [...]
Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer
Currently, it is difficult for clinicians to decide which patients [...]
The future of immunotherapy-based combinations for metastatic kidney cancer
The past decade or so has seen the development of [...]
Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone
A recent phase II clinical trial has shown that combined [...]
PD-L1 can be used to predict the likely course of kidney cancer
A recently published study evaluated the role of programmed-death receptor [...]
PD-L1 expression and clinical outcomes with targeted therapy
A recent study published in Clinical Cancer Research analysed tumour [...]
Immune checkpoint inhibitors are more effective in PD-L1 positive patients
Immune checkpoint inhibitors, such as nivolumab, ipilimumab or pembrolizumab are [...]
ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study
Results from the biomarker analysis from the JAVALIN Renal 101 [...]
Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
Results from this phase III trial of atezolizumab plus bevacizumab [...]
Avelumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
